Post-marketing study of Remsima in patients from South Korea with inflammatory bowel disease

Trial Profile

Post-marketing study of Remsima in patients from South Korea with inflammatory bowel disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs Infliximab (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Oct 2015 New trial record
    • 27 Oct 2015 Results published in the Expert Review of Gastroenterology and Hepatology, according to Celltrion media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top